Diabetes

Emerging data show glucagon-like peptide-1 receptor agonists may raise the risk of certain autoimmune diseases compared with other diabetes drugs.

A new analysis shows that socioeconomic status shrinks type 2 diabetes risk far more for nonHispanic white and Asian Americans than for nonHispanic Black and Hispanic Americans.

New case-control study finds that patients with type 2 diabetes and more severe depressive symptoms show higher cortisol, higher hemoglobin A1C, and lower insulin.

Data show bone density and lean mass losses can be clinically meaningful, but case reports point to resistance training as effective countermeasures.

The filing acceptance marks a step toward lower-cost alternatives to Mounjaro and Zepbound.

Episode 12 explores recent updates from the 2026 ADA Scientific Sessions, highlighting for pharmacists which technologies are making waves in the diabetes space right now.

Bryan Wheeler, PharmD, discusses how the Medicare GLP-1 Bridge program works and what it means for independent pharmacy operations.

Pharmacists leverage CGM and automated insulin delivery to personalize diabetes care, prevent errors, and expand equitable access to technology.

A drug already used to protect the kidneys may now offer a broader shield.

Diabetes technology shifts to continuous glucose monitoring, automated insulin delivery, and connected pens, empowering pharmacists to guide safer care.

The ACTIV-6 trial suggests early metformin may halve clinician-diagnosed long COVID risk, offering a low-cost option pharmacists can apply safely.

This decision marks a milestone in clinical pharmacy as it targets the underlying autoimmune destruction of pancreatic beta cells.

FDA clears first OTC CGM for children 2 years and older, expanding tracking beyond prescriptions for pediatric populations.

Pharmacists close these gaps through screening and prevention for patients.

Once-weekly mazdutide drives approximately 17% weight loss in Chinese adults with obesity, offering a dual GLP-1/glucagon metabolic option.

Medicare’s $35 insulin cap cuts cost swings, boosts adherence for high-burden patients, and highlights pharmacists’ role in preventing rationing.

New 9-year data shows some high-risk prediabetes patients progress to type 2 diabetes despite 8% weight loss.

In an evolving health care landscape bringing all providers into a primary care team, diabetes is no different and the pharmacist community can offer so much for patients.

Episode 11 addresses recent changes to the AACE diabetes guidelines and what pharmacists need to do to stay informed.

In part 2 of our interview with Sandra Leal, PharmD, MPH, she explored the ADA Standards of Care and how pharmacists are positioned to assist in interoperable diabetes management.

Older adults with type 2 diabetes often juggle 5 or more different prescriptions.

This regulatory milestone establishes inhaled insulin as the first and only noninjectable mealtime insulin option for children and adolescents.

Real-world data show GLP-1 drugs in type 1 diabetes cut heart and kidney risks, support weight loss, and appear safe with insulin adjustments.

As diabetes rises to be one of the most prominent chronic diseases globally, pharmacists have reached out as key resources for preventing and managing its complications.

Meta-analysis shows empagliflozin is superior to sitagliptin with metformin for glycemic control.